18 F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18 F-Florbetapir in Alzheimer’s Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis
Authors:
- 12 July 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 70 (4) , 1197-1207
Abstract
Background: 18 F-Fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and 18 F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Objectives: This study aims to compare the efficacy of 18 F-FDG and 18 F-florbetapir PET at evaluating the cognitive performance of patients with AD, MCI, and normal controls (NC). Methods: 63 subjects (36 male/27 female, mean age = 68.3) including 19 AD, 23 MCI, and 21 NC underwent 18 F-FDG and 18 F-florbetapir PET imaging. A global quantification approach was applied on supra-tentorial, frontal, parieto-occipital, temporal, and cerebellar brain regions by calculating the global SUVmean ratios (GSUVr) as the weighted average of all regional SUVmean. 18 F-FDG and 18 F-florbetapir GSUVr of each region were subsequently correlated with the Mini-Mental State Examination (MMSE). Results: Subjects were studied in five categories as NC, MCI patients, AD patients, MCI and AD patients grouped together (MCI/AD), and a group including all the subjects (NC/MCI/AD). Both 18 F-FDG and 18 F-florbetapir could successfully detect subjects with dementia ( p < 0.001). Studied in all regions and groups, the correlation analysis of 18 F-FDG GSUVr with MMSE scores was significant in more regions and groups compared to that of 18 F-florbetapir. We also demonstrated that the correlation of 18 F-FDG GSUVr with MMSE is stronger than that of 18 F-florbetapir in the supra-tentorial and temporal regions. Conclusions: This study reveals how 18 F-FDG-PET global quantification is a superior indicator of cognitive performance in AD and MCI patients compared to 18 F-florbetapir PET. Accordingly, we still recommend 18 F-FDG-PET over amyloid imaging in the evaluation for AD and MCI.Keywords
This publication has 61 references indexed in Scilit:
- Brain Amyloid Imaging — FDA Approval of Florbetapir F18 InjectionNew England Journal of Medicine, 2012
- In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)Journal of Nuclear Medicine, 2010
- Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studiesNeuroImage, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)NeuroImage, 2009
- Amyloid imaging in mild cognitive impairment subtypesAnnals of Neurology, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain, 2008
- Limbic hypometabolism in Alzheimer's disease and mild cognitive impairmentAnnals of Neurology, 2003
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984